David Bredt insider trades
Open-market stock purchases and sales by David Bredt, Chief Scientific Officer at Rapport Therapeutics, Inc, from SEC Form 4 filings since Jun 6, 2024.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Feb 19, 2026 | RAPP Rapport Therapeutics, Inc | Bought (not open market) | — |
| Feb 17, 2026 | RAPP Rapport Therapeutics, Inc | Sold | $25.2K |
| Feb 17, 2026 | RAPP Rapport Therapeutics, Inc | Sold | $156K |
| Feb 17, 2026 | RAPP Rapport Therapeutics, Inc | Sold | $65.1K |
| Feb 2, 2026 | RAPP Rapport Therapeutics, Inc | Bought (not open market) | — |
| Jan 15, 2026 | RAPP Rapport Therapeutics, Inc | Sold | $223K |
| Jan 15, 2026 | RAPP Rapport Therapeutics, Inc | Sold | $5.5K |
| Dec 31, 2025 | RAPP Rapport Therapeutics, Inc | Sold (not open market) | — |
| Dec 31, 2025 | RAPP Rapport Therapeutics, Inc | Sold | $197K |
| Dec 15, 2025 | RAPP Rapport Therapeutics, Inc | Sold | $231K |
| Dec 15, 2025 | RAPP Rapport Therapeutics, Inc | Sold | $24.4K |
| Nov 17, 2025 | RAPP Rapport Therapeutics, Inc | Sold | $78.4K |
| Nov 17, 2025 | RAPP Rapport Therapeutics, Inc | Sold | $136K |
| Oct 15, 2025 | RAPP Rapport Therapeutics, Inc | Sold | $191K |
| Oct 15, 2025 | RAPP Rapport Therapeutics, Inc | Sold | $28.3K |
Companies traded
- RAPP Rapport Therapeutics, Inc: 21 sales, last Feb 19, 2026